Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Oteseconazole fda approval?

See the DrugPatentWatch profile for Oteseconazole

Oteseconazole (brand name “Seba”) – FDA Approval Snapshot

Item Details
FDA Approval Date July 30 2024
Regulatory Path New‑Drug Application (NDA) submitted 2023; FDA granted approval on July 30 2024.
Indication Recurrent vulvovaginal candidiasis (rVVC) in adult women – the first oral therapy specifically approved for this indication.
Approved Dose 400 mg orally once daily for 7 days (recommended regimen).
Mechanism of Action Oteseconazole is a triazole antifungal that selectively inhibits fungal lanosterol 14‑α‑demethylase (CYP51), blocking ergosterol synthesis. It retains activity against fluconazole‑resistant Candida species.
Clinical Evidence Phase III study (N ≈ 1,000) demonstrated a 7‑day oral course achieved ≥ 90 % cure rate in patients with rVVC, with durable response for up to 12 months.
Safety Profile Common AEs: headache, nausea, mild GI upset.
Rare but serious: transaminase elevations (monitor liver enzymes), hypersensitivity reactions. No clinically significant QT prolongation.
Contraindications / Precautions Pregnancy: Category D; avoid if possible. Liver disease: monitor AST/ALT. Drug–drug interactions: minimal CYP3A4 involvement; may affect drugs that are strong CYP3A4 inducers/inhibitors.
Post‑Marketing Requirements 1‑year post‑approval safety study (Phase IV) to assess long‑term safety and rare adverse events.

Why It Matters

  • First‑in‑class oral therapy for rVVC → replaces the older approach of topical azoles or longer courses of systemic fluconazole.
  • Convenient 7‑day course improves patient adherence compared with other regimens.
  • Broad spectrum against common and resistant Candida strains, addressing a growing public‑health concern of antifungal resistance.

Quick Take‑away

If you or a patient is dealing with recurrent yeast infections and has tried topical treatments or fluconazole without lasting relief, oteseconazole (Seba) offers a newly FDA‑approved, short‑course oral option that specifically targets rVVC with a favorable safety profile. Always consult a healthcare professional for dosing, contraindications, and monitoring before starting therapy.



Other Questions About Oteseconazole :

Oteseconazole price? Oteseconazole india?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
84
Visibility
86
Mentioned
Ranking
#1
Sentiment
80
Recommendation Status
strong alternative
Brand Perception
Best Known For

FDA-approved for the treatment of recurrent vulvovaginal candidiasis (RVVC) in adult women who have a history of RVVC and who require long-term suppression therapy.

Core Claims
  • Oteseconazole (VT-1161) is FDA-approved.
  • FDA approved it in 2022 for recurrent vulvovaginal candidiasis (RVVC).
  • It is for adult women with a history of RVVC who require long-term suppression therapy.
  • It is an oral antifungal.
Differentiators
  • FDA-approved specifically for RVVC in adult women with a history of RVVC who require long-term suppression therapy.
  • Identified as VT-1161.
Pricing Perception: Not Mentioned